UroGen Pharma Stock Forecast - Naive Prediction
| URGN Stock | USD 21.08 1.08 5.40% |
UroGen Stock outlook is based on your current time horizon. Although UroGen Pharma's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of UroGen Pharma's systematic risk associated with finding meaningful patterns of UroGen Pharma fundamentals over time.
As of today, the RSI of UroGen Pharma's share price is approaching 49. This usually implies that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling UroGen Pharma, making its price go up or down. Momentum 49
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.47) | EPS Estimate Current Year (3.14) | EPS Estimate Next Year (0.97) | Wall Street Target Price 35.25 | EPS Estimate Current Quarter (0.68) |
Using UroGen Pharma hype-based prediction, you can estimate the value of UroGen Pharma from the perspective of UroGen Pharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards UroGen Pharma using UroGen Pharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards UroGen using crowd psychology based on the activity and movement of UroGen Pharma's stock price.
UroGen Pharma Short Interest
An investor who is long UroGen Pharma may also wish to track short interest. As short interest increases, investors should be becoming more worried about UroGen Pharma and may potentially protect profits, hedge UroGen Pharma with its derivative instruments, or be ready for some potential downside.
200 Day MA 16.9576 | Short Percent 0.207 | Short Ratio 11.5 | Shares Short Prior Month 7.7 M | 50 Day MA 23.1554 |
UroGen Relative Strength Index
The Naive Prediction forecasted value of UroGen Pharma on the next trading day is expected to be 19.16 with a mean absolute deviation of 1.16 and the sum of the absolute errors of 71.88.UroGen Pharma Hype to Price Pattern
Investor biases related to UroGen Pharma's public news can be used to forecast risks associated with an investment in UroGen. The trend in average sentiment can be used to explain how an investor holding UroGen can time the market purely based on public headlines and social activities around UroGen Pharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of UroGen Pharma's market sentiment to its price can help taders to make decisions based on the overall investors consensus about UroGen Pharma.
UroGen Pharma Implied Volatility | 0.87 |
UroGen Pharma's implied volatility exposes the market's sentiment of UroGen Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if UroGen Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that UroGen Pharma stock will not fluctuate a lot when UroGen Pharma's options are near their expiration.
The Naive Prediction forecasted value of UroGen Pharma on the next trading day is expected to be 19.16 with a mean absolute deviation of 1.16 and the sum of the absolute errors of 71.88. UroGen Pharma after-hype prediction price | USD 21.08 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of UroGen Pharma to cross-verify your projections. Prediction based on Rule 16 of the current UroGen contract
Based on the Rule 16, the options market is currently suggesting that UroGen Pharma will have an average daily up or down price movement of about 0.0544% per day over the life of the 2026-03-20 option contract. With UroGen Pharma trading at USD 21.08, that is roughly USD 0.0115 . If you think that the market is fully incorporating UroGen Pharma's daily price movement you should consider acquiring UroGen Pharma options at the current volatility level of 0.87%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-03-20 UroGen Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast UroGen Pharma's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in UroGen Pharma's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for UroGen Pharma stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current UroGen Pharma's open interest, investors have to compare it to UroGen Pharma's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of UroGen Pharma is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in UroGen. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
UroGen Pharma Additional Predictive Modules
Most predictive techniques to examine UroGen price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for UroGen using various technical indicators. When you analyze UroGen charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
UroGen Pharma Cash Forecast
Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the UroGen Pharma's financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 2014-12-31 | Previous Quarter 92.9 M | Current Value 90 M | Quarterly Volatility 58 M |
UroGen Pharma Naive Prediction Price Forecast For the 28th of January
Given 90 days horizon, the Naive Prediction forecasted value of UroGen Pharma on the next trading day is expected to be 19.16 with a mean absolute deviation of 1.16, mean absolute percentage error of 2.09, and the sum of the absolute errors of 71.88.Please note that although there have been many attempts to predict UroGen Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that UroGen Pharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
UroGen Pharma Stock Forecast Pattern
| Backtest UroGen Pharma | UroGen Pharma Price Prediction | Buy or Sell Advice |
UroGen Pharma Forecasted Value
In the context of forecasting UroGen Pharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. UroGen Pharma's downside and upside margins for the forecasting period are 14.29 and 24.03, respectively. We have considered UroGen Pharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of UroGen Pharma stock data series using in forecasting. Note that when a statistical model is used to represent UroGen Pharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 120.6874 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 1.1593 |
| MAPE | Mean absolute percentage error | 0.0506 |
| SAE | Sum of the absolute errors | 71.878 |
Predictive Modules for UroGen Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as UroGen Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.UroGen Pharma After-Hype Price Density Analysis
As far as predicting the price of UroGen Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in UroGen Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of UroGen Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
UroGen Pharma Estimiated After-Hype Price Volatility
In the context of predicting UroGen Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on UroGen Pharma's historical news coverage. UroGen Pharma's after-hype downside and upside margins for the prediction period are 16.24 and 25.92, respectively. We have considered UroGen Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
UroGen Pharma is somewhat reliable at this time. Analysis and calculation of next after-hype price of UroGen Pharma is based on 3 months time horizon.
UroGen Pharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as UroGen Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading UroGen Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with UroGen Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.22 | 4.87 | 0.13 | 0.00 | 10 Events / Month | 7 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
21.08 | 21.08 | 0.00 |
|
UroGen Pharma Hype Timeline
UroGen Pharma is at this time traded for 21.08. The entity has historical hype elasticity of 0.13, and average elasticity to hype of competition of 0.0. UroGen is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at 0.22%. %. The volatility of related hype on UroGen Pharma is about 32466.67%, with the expected price after the next announcement by competition of 21.08. About 98.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 239.57. UroGen Pharma recorded a loss per share of 3.47. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Historical Fundamental Analysis of UroGen Pharma to cross-verify your projections.UroGen Pharma Related Hype Analysis
Having access to credible news sources related to UroGen Pharma's direct competition is more important than ever and may enhance your ability to predict UroGen Pharma's future price movements. Getting to know how UroGen Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how UroGen Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| KOD | Kodiak Sciences | (0.65) | 8 per month | 4.22 | 0.1 | 10.04 | (6.87) | 25.07 | |
| MNMD | Mind Medicine | 0.19 | 9 per month | 3.40 | 0.08 | 6.21 | (4.21) | 28.06 | |
| XNCR | Xencor Inc | (0.14) | 8 per month | 3.21 | (0.01) | 7.05 | (5.08) | 16.84 | |
| TNGX | Tango Therapeutics | (0.41) | 10 per month | 4.05 | 0.08 | 11.29 | (6.24) | 31.20 | |
| NRIX | Nurix Therapeutics | 0.33 | 8 per month | 2.58 | 0.20 | 9.23 | (4.80) | 27.63 | |
| OCS | Oculis Holding AG | 0.50 | 10 per month | 2.00 | 0.1 | 5.79 | (4.03) | 15.08 | |
| BBOT | BridgeBio Oncology Therapeutics | (0.72) | 8 per month | 3.36 | 0.05 | 5.98 | (5.93) | 27.79 | |
| ANAB | AnaptysBio | 1.45 | 8 per month | 3.45 | 0.13 | 6.11 | (5.26) | 20.41 | |
| PHAT | Phathom Pharmaceuticals | (0.30) | 10 per month | 3.66 | (0) | 5.99 | (4.86) | 24.16 | |
| PROK | ProKidney Corp | (0.10) | 8 per month | 0.00 | (0.13) | 5.77 | (8.95) | 22.38 |
Other Forecasting Options for UroGen Pharma
For every potential investor in UroGen, whether a beginner or expert, UroGen Pharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. UroGen Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in UroGen. Basic forecasting techniques help filter out the noise by identifying UroGen Pharma's price trends.UroGen Pharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with UroGen Pharma stock to make a market-neutral strategy. Peer analysis of UroGen Pharma could also be used in its relative valuation, which is a method of valuing UroGen Pharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
UroGen Pharma Market Strength Events
Market strength indicators help investors to evaluate how UroGen Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading UroGen Pharma shares will generate the highest return on investment. By undertsting and applying UroGen Pharma stock market strength indicators, traders can identify UroGen Pharma entry and exit signals to maximize returns.
UroGen Pharma Risk Indicators
The analysis of UroGen Pharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in UroGen Pharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting urogen stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.46 | |||
| Semi Deviation | 3.96 | |||
| Standard Deviation | 4.97 | |||
| Variance | 24.73 | |||
| Downside Variance | 16.99 | |||
| Semi Variance | 15.69 | |||
| Expected Short fall | (4.29) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for UroGen Pharma
The number of cover stories for UroGen Pharma depends on current market conditions and UroGen Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that UroGen Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about UroGen Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
UroGen Pharma Short Properties
UroGen Pharma's future price predictability will typically decrease when UroGen Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of UroGen Pharma often depends not only on the future outlook of the potential UroGen Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. UroGen Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 42.9 M | |
| Cash And Short Term Investments | 236.7 M |
Check out Historical Fundamental Analysis of UroGen Pharma to cross-verify your projections. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.47) | Revenue Per Share | Quarterly Revenue Growth 0.09 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.